Humana (NYSE:HUM) Price Target Raised to $407.00

Humana (NYSE:HUM) had its target price hoisted by TD Cowen from $396.00 to $407.00 in a research report sent to investors on Wednesday morning, Benzinga reports. They currently have a buy rating on the insurance provider’s stock.

Several other equities analysts also recently commented on the stock. The Goldman Sachs Group lowered their target price on shares of Humana from $450.00 to $385.00 and set a buy rating on the stock in a report on Wednesday, April 3rd. Bank of America upped their price target on shares of Humana from $342.00 to $376.00 and gave the company a neutral rating in a research note on Monday, May 20th. Piper Sandler started coverage on shares of Humana in a research note on Wednesday, June 26th. They set an overweight rating and a $392.00 price target on the stock. Truist Financial upped their price target on shares of Humana from $355.00 to $400.00 and gave the company a hold rating in a research note on Monday, July 15th. Finally, Jefferies Financial Group decreased their price target on shares of Humana from $411.00 to $381.00 and set a buy rating on the stock in a research note on Monday, April 22nd. Fourteen equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of Hold and an average target price of $402.60.

Humana Price Performance

HUM stock opened at $392.63 on Wednesday. Humana has a one year low of $298.61 and a one year high of $530.54. The company’s fifty day moving average price is $365.66 and its 200-day moving average price is $347.24. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.67 and a current ratio of 1.67. The company has a market capitalization of $47.31 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 2.23 and a beta of 0.51.

Humana (NYSE:HUM) last released its earnings results on Wednesday, April 24th. The insurance provider reported $7.23 EPS for the quarter, topping the consensus estimate of $6.12 by $1.11. Humana had a net margin of 1.82% and a return on equity of 17.76%. The firm had revenue of $29.61 billion for the quarter, compared to the consensus estimate of $28.52 billion. During the same quarter in the previous year, the firm earned $9.38 earnings per share. The company’s quarterly revenue was up 10.7% compared to the same quarter last year. On average, equities analysts anticipate that Humana will post 16.27 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Kintegral Advisory LLC raised its position in shares of Humana by 14.6% in the 2nd quarter. Kintegral Advisory LLC now owns 3,957 shares of the insurance provider’s stock valued at $1,482,000 after purchasing an additional 504 shares during the last quarter. Conning Inc. raised its position in shares of Humana by 5.7% in the 2nd quarter. Conning Inc. now owns 971 shares of the insurance provider’s stock valued at $363,000 after purchasing an additional 52 shares during the last quarter. Leith Wheeler Investment Counsel Ltd. raised its position in shares of Humana by 80.4% in the 2nd quarter. Leith Wheeler Investment Counsel Ltd. now owns 65,587 shares of the insurance provider’s stock valued at $24,507,000 after purchasing an additional 29,227 shares during the last quarter. Checchi Capital Advisers LLC raised its position in shares of Humana by 11.3% in the 2nd quarter. Checchi Capital Advisers LLC now owns 1,414 shares of the insurance provider’s stock valued at $528,000 after purchasing an additional 144 shares during the last quarter. Finally, Harbour Investments Inc. raised its position in shares of Humana by 10.5% in the 2nd quarter. Harbour Investments Inc. now owns 432 shares of the insurance provider’s stock valued at $161,000 after purchasing an additional 41 shares during the last quarter. 92.38% of the stock is currently owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.